

11. (new) Use of the vaccine of claim 8 for eliciting long-lasting protective antiviral immune responses against influenza viruses.

12. (new) A plasmid vector construct pCI-HA10 comprising a gene encoding for hemagglutinin protein and capable of expressing said hemagglutinin protein in a host.

13. (new) A method for constructing a plasmid pCI-HA10 comprising the following steps:

- (1) amplifying hemagglutinin gene from viral and mRNA with PCR;
- (2) inserting and ligating the hemagglutinin gene into a pCI vector;
- (3) transforming the resulting vector into competent E.coli DH5 $\alpha$  cells;
- (4) transcribing and translating of pCI-HA10; and
- (5) preparing and purifying pCI-HA10 by bulk preparation method.

91 14. (new) A liposome formulation for encapsulating the plasmid pCI-HA10 of claim 12 comprising of 7% 1,2 dioleoyl-3-dimethylammonium chloride (DODAC), 78% 1,2-dioleoyl-sn-glycerol-3-phospho-ethanolamine (DOPE) and 15% polyethylene glycol C8 ceramide (PEG<sub>2000</sub>C<sub>8</sub>CER).

15. (new) A method for encapsulating the plasmid pCI-HA10 of claim 12 into liposomes comprising the following steps:

- (1) preparing 7% DODAC, 78% DOPE, and 15% PEG<sub>2000</sub>C<sub>8</sub>CER at 10mg/ml concentrations to form a lipid film at 50 °C for 2h under vacuum;
- (2) incubating the lipid film at 50 °C for 2h under vacuum;
- (3) reconstituting the lipid film with distilled water and 1M  $\beta$ -octylglucanopyranoside detergent at 20% of the total preparation volume;

(4) adding the plasmid DNA to the lipid film at a concentration of 400 µg DNA/ml of 10 mg/ml;

(5) transferring the reconstituted preparation into dialysis tubing and dialyzing in 1X HEPES buffer solution (150 mM NaCl, 20 mM Hepes, pH 7.4) at 23 °C for 15 h; and

(6) removing the free, non-encapsulate DNA from encapsulated DNA on a DEAE Sepharose CL-6B anion exchange column.

16. (new) A liposome-encapsulated pCI-HA10 constructed in accordance with the method of claim 15.

A<sub>1</sub>  
17. (new) A method of delivering the liposome-encapsulated pCI-HA10 of claim 16 to a respiratory tract using intranasal administration, and/or aerosol inhalation to eliciting protective antiviral immune responses to influenza viruses.

18. (new) A method for preventing and/or treating influenza virus infection, comprising administering to a patient in need thereof a pharmaceutically effective amount of the vaccine of claim 8.

19. (new) A method for eliciting long-lasting protective antiviral immune responses against influenza viruses, comprising administering to a patient in need thereof a pharmaceutically effective amount of the vaccine of claim 8.

---

**REMARKS/ARGUMENTS**

This is a full and timely response to the non-final office action of December 16, 2002. Reexamination and reconsideration are courteously requested.